Interpace Biosciences Inc EV/EBIT
Mi az Interpace Biosciences Inc EV/EBIT?
A EV/EBIT az Interpace Biosciences Inc - 1.01
Mi a EV/EBIT meghatározása?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT a Health Care szektor a NASDAQ-on cégekben a Interpace Biosciences Inc -hoz képest
Mit csinál Interpace Biosciences Inc?
advancing patient care through molecular diagnostic testing. interpace diagnostics develops molecular diagnostic tests. our molecular diagnostic tests provide unparalleled accuracy and clarity to improve outcomes in patients facing a cancer diagnosis. you can be assured that all of the molecular tests we offer are driven by rigorous, validated science. we power the future of molecular diagnostics, delivering cutting-edge and much-needed mutational analysis that helps risk-stratify for thyroid, pancreatic, and other cancers to better inform treatment decisions. the unique molecular diagnostic tests we offer enable healthcare providers to avoid unnecessary surgeries and better assess the risk of cancer progression in their patients.
ev/ebit -hoz hasonló cégek Interpace Biosciences Inc
- Recylex S.A nak EV/EBIT 0.99 van
- Imunon Inc nak EV/EBIT 1.00 van
- STM Plc nak EV/EBIT 1.00 van
- A.P. Moller - Marsk A/S nak EV/EBIT 1.00 van
- SandRidge Permian Trust nak EV/EBIT 1.00 van
- Inozyme Pharma nak EV/EBIT 1.01 van
- Interpace Biosciences Inc nak EV/EBIT 1.01 van
- Ekotechnika Ag A O.N nak EV/EBIT 1.02 van
- Cato nak EV/EBIT 1.02 van
- Phio Pharmaceuticals nak EV/EBIT 1.05 van
- United Oil & Gas Plc nak EV/EBIT 1.05 van
- Virnetx Corp nak EV/EBIT 1.07 van
- InMed Pharmaceuticals nak EV/EBIT 1.07 van